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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of ribavirin for treating people with Crimean Congo Haemorrhagic Fever (CCHF).
B A C K G R O U N D
Description of the condition
Crimean Congo haemorrhagic fever (CCHF) is a tick-borne viral
disease. The virus that causes CCHF is a Nairovirus, a member
of the Bunyaviridiae family. The most common vector of the dis-
ease are Hyalomma ticks, which spread the disease and also act
as a disease reservoir. CCHF is found in Africa, Eastern Europe,
the Middle East, and Asia, with further occasional cases in other
European countries such as Spain and Greece (Hoogstraal 1979;
Zapata 2014; García Rada 2016).
The disease starts with a headache, fever, abdominal pain, mus-
culoskeletal pain, and nausea. Over the next few days this is then
followed by gastrointestinal symptoms, including vomiting, diar-
rhoea, and haemorrhagic rash. After three to five days, a minor-
ity of patients progress to severe microvascular instability and the
haemorrhagic phase of illness, which is usually manifested first
by a petechial rash followed by ecchymosis and bleeding. As the
disease progresses into the second week, bleeding can worsen and
become characteristically more severe, resulting most commonly
in haemorrhage under the skin and within the abdomen. Infection
in people is usually due to a tick bite or via contact with infected
bodily fluids from humans or animals (Ergönül 2006).
Many infections occur without symptoms and some estimates sug-
gest this occurs in most infections (Bodur 2012). CCHF severity
in people who are clinically unwell varies. Different scores to as-
sess severity are used but it remains unclear what proportion of all
infections are severe (Swanepoel 1987; Dokuzoguz 2013).
Those at highest risk of contracting the virus are people who work
outdoors in CCHF-endemic areas, those who work with large
domestic animals, and healthcare workers (Whitehouse 2004).
CCHF has been linked to reservoirs such as sheep, goats, hedge-
hogs, and hares (Causey 1970; Saluzzo 1985; Yen 1985; Shepherd
1987). Human-to-human transmission occurs within families and
in healthcare settings, including nosocomial outbreaks. The great-
est risk of nosocomial exposure is from splash exposures and nee-
dle stick injuries (Conger 2015; Leblebicioglu 2016). Case series
studies also suggest that in rare cases airborne transmission from
ventilated patients may also occur (Pshenichnaya 2015). Case re-
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ports suggest possible sexual transmission, although there is no
published evidence of the virus being present in seminal or vaginal
fluid (Pshenichnaya 2016). The virus is also transmitted from per-
son-to-person by infected bodily fluids, and is highly infectious.
Death rates in people infected can reach up to 50% (Hoogstraal
1979). In endemic areas where high-quality supportive care and
access to diagnostics are offered, death rates can be as low as 5%
(Leblecioglu 2016).
The disease may become more important in future years because
of changes to the habitat of the Hyalomma tick vector, which is
due in part to changes in the rural landscape from large diffuse
habitats to smaller habitats. This is shown to lead to densely pop-
ulated habitats for the tick vector, which is associated with increas-
ing incidence of the disease (Estrada-Peña 2007). Given the high
mortality of patients, the lack of a widely available viable vaccine
(Dowall 2016), and an emerging pattern of spread with multi-
ple countries reporting re-emergence of epidemics or new cases
(Messina 2015), CCHF should be considered a potential threat
to public health.
Description of the intervention
Supportive medical care underpins CCHF treatment, and use
of fluids, good nursing care, and blood products in response to
changes in the blood’s ability to clot are a key components of this
(Leblebicioglu 2012). Previous attempts at therapeutic regimens
have explored intravenous (IV) immunoglobulin isolated from
horses (Hoogstraal 1979), and from recovered patients (Vassilenko
1990), but these are not currently widely used.
Ribavirin is a synthetic nucleoside that is active against a broad
spectrum of DNA and RNA viruses (Sidwell 1972). It is one of
few drugs shown to be active against CCHF in vitro (Watts 1989).
Observational studies show that it could be effective in treating
cases of CCHF (Fisher-Hoch 1995; Mardani 2003; Dokuzoguz
2013), although this has been debated (Kalin 2014; Leblebicioglu
2016). Ribavirin is used with interferon to treat people who have
Hepatitis C, and is used alone in treating people who have Lassa
fever (Debing 2013). Ribavirin is also used in healthcare settings
as a form of post-exposure prophylaxis (Leblebicioglu 2016).
Ribavirin has adverse effects, and, alongside the questions about its
efficacy, clinicians debate whether to use the drug or not (Ceylan
2013; Oflaz 2015). Some of the adverse effects include risks of
haemolysis, arrhythmia, bone marrow suppression, and deranged
liver function (EMA 2015). Two previous systematic reviews have
shownno clear benefit of ribavirin in people withCCHF, although
the available evidence is limited mainly to confounded observa-
tional data (Soares-Weiser 2010; Ascioglu 2011).
No alternative therapy has been proposed as the mainstay of ther-
apeutic treatment. Although newer drugs, such as favipiravir, have
shown promise in vitro (Oestereich 2014), widespread adoption
of new therapies is years away. Current treatment guidelines vary
from region to region and country to country, and guidance on
who and when to treat with ribavirin varies (DoH South Africa
2014; Kalin 2014).
How the intervention might work
Ribavirin can be given in hospital settings either intravenously
or orally, according to World Health Organization (WHO) rec-
ommendations (WHO2015). National guidelines from countries
such as South Africa (DoH South Africa 2014), India (NCDC
2011), and Pakistan (NIH 2013), recommend prompt treatment
with ribavirin following diagnosis of CCHF. However, these rec-
ommendations formanagement are not based on a robust evidence
base (Soares-Weiser 2010). CCHF can be mild or more severe as
a disease, and often it is not deemed necessary to treat mild cases
of the disease (Ergönül 2004). Questions remain about the overall
benefits of ribavirin, how long after the onset of symptoms is it
most effective, and whether it is more or less effective in severe
cases (Ergönül 2006; Dokuzoguz 2013; Leblecioglu 2016).
Existing studies have mostly been observational in design; there-
fore conclusions previously drawn from these studies are limited.
However, administration of ribavirin early in the disease, when it
appears to be at its most effective, has been found to be a promis-
ing approach (Dokuzoguz 2013; Ozbey 2014). This fits with the
known course of the disease, where the virus is most commonly
only present in the blood within the first week following onset of
CCHF symptoms (Bente 2013).
Why it is important to do this review
In recent years, CCHF incidence has been increasing in several
areas worldwide (Zapata 2014). The controversy surrounding rib-
avirin use and the benefits of a widely available treatment for
CCHF mean an up-to-date review of the existing evidence is re-
quired. There are mixed views on whether to treat CCHFwith rib-
avirin given the questions over the balance between potential but
unprovenbenefit andknown risks of the drug (Kalin 2014). There-
fore it is important to use the data available to address whether rib-
avirin reduces the number of deaths fromadiseasewheremany die,
whilst assessing the possibility of harm from serious, life-threaten-
ing adverse effects.
O B J E C T I V E S
To assess the effects of ribavirin for treating people with Crimean
Congo Haemorrhagic Fever (CCHF).
M E T H O D S
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Criteria for considering studies for this review
Types of studies
• Randomized controlled trials (RCTs), quasi-RCTs, and
non-randomized controlled studies of ribavirin compared to any
other treatment.
• Cohort studies with ribavirin compared to any other
treatment schedule (prospective and retrospective).
• Case-control studies with ribavirin compared to any other
treatment schedule.
If data are insufficient by consensus within the review author team,
we will also summarize the following cohort studies without com-
parators (prospective or retrospective), cross-sectional studies, and
case series (more than 10 cases).
Types of participants
Children or adults of any age with a confirmed case of CCHF with
a laboratory test (immunoglobulin or polymerase chain reaction
(PCR)).
Types of interventions
Intervention
Ribavirin (intravenous (IV) or oral).
Control
Supportive care only.
Types of outcome measures
Primary outcomes
• Death (in hospital or 28 days post-admission).
Secondary outcomes
• Death (in hospital or 28 days post-admission) amongst
those receiving ribavirin within five days of onset of symptoms
and death in those receiving ribavirin after five days.
• Length of hospital stay (days).
• Requirement for transfusion (any blood products, including
platelets, fresh frozen plasma, packed red cells, or whole blood).
• Withdrawal of treatment due to serious adverse events.
• Serious adverse events as defined according to the accepted
US Food and Drug Administration (FDA) definition of: “if in
the view of the investigator or sponsor, the event results in any of
the following outcomes: death, life threatening adverse event,
inpatient hospitalizations, prolongation of existing
hospitalization, disability or permanent damage, congenital
abnormality, required intervention to prevent permanent
impairment or other serious medical events” (FDA 2016).
Search methods for identification of studies
Wewill attempt to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We will search the following databases using the search terms and
strategy described in Appendix 1: the Cochrane Infectious Dis-
eases Group Specialized Register; the Central Register of Con-
trolled Trials (CENTRAL), published in the Cochrane Library;
MEDLINE (PubMed); Embase (OVID); Science Citation Index-
Expanded, Social Sciences Citation index, conference proceedings
(Web of Science); and CINAHL (EBSCOHost). We will search
regional databases as indicated by the World Health Organiza-
tion (WHO). We will also search the WHO International Clini-
cal Trials Registry Platform (ICTRP; www.who.int/ictrp/en/) and
ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home) for trials in
progress, using “ribavirin” and “Crimean Congo haemorrhagic
fever” or CCHF as search terms.
Searching other resources
Wewill search the reference lists of any relevant systematic reviews.
We will contact researchers in the field, request information about
grey literature and ongoing studies from the WHO, and check
reference lists of included studies.
Data collection and analysis
Selection of studies
Two review authors will independently screen all citations and ab-
stracts identified in the search according to predefined inclusion
criteria, as outlined above. We will obtain the full-text reports of
all potentially eligible studies or studies we are unclear about. Two
review authors will independently screen these full-text articles.
We will resolve any disagreements through discussion and if nec-
essary we will consult a third review author. We will list all studies
excluded after full-text assessment and their reasons for exclusion
in a ’Characteristics of excluded studies’ table. We will illustrate
the study selection process in a PRISMA diagram.
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Data extraction and management
One review author will extract data using pre tested data extrac-
tion forms. A second review author will crosscheck the extracted
data. We will resolve any disagreements about data extraction by
referring to the study report and through discussion. We will at-
tempt to contact the study authors where data are insufficient or
missing.
We will extract data using a tool individualized for the inclusion
criteria described above, including dose and method of adminis-
tration (oral or IV) adult or paediatric populations, location, set-
ting, design, study size, dates, and various clinical parameters.
Assessment of risk of bias in included studies
Two review authors will assess the risk of bias of each in-
cluded study; we will resolve any disagreements through dis-
cussion and we will consult a third review author if necessary.
For RCTs or quasi-RCTs, we will use the Cochrane Risk of Bias
tool for RCTs (Higgins 2011a). For observational studies, we will
use the Cochrane Risk Of Bias In Non-randomized Studies - of
Interventions (ROBINS-I); (Sterne 2016).
We will use ROBINS-I to assess the risk of bias for all included
observational studies.Wewill assess risk of bias through ahierarchy
of domains, starting with critical then serious, moderate, and low.
If any domain reaches critical risk of bias we will not continue
with the assessment, as further evaluation will not influence how
we assess the certainty of the evidence.
We will perform an analysis that only includes RCTs and obser-
vational studies at serious, moderate, or low risk of bias.
We will perform an analysis of data including studies with a critical
risk of bias if this helps understanding of obvious confounding
and provides an assessment of the degree to which confounding
may influence effect estimates.
Measures of treatment effect
For dichotomous outcomes, we will use risk ratios (RR) with their
95% confidence intervals (CIs). For continuous data we will use
mean differences with their 95% CIs.
Unit of analysis issues
For cluster-RCTs, or cluster non-randomized trials, we will extract
adjusted measures of effect where possible. If the included study
does not perform any adjustment for clustering, we will adjust
the raw data ourselves using an intra cluster correlation coefficient
(ICC). If the study authors do not report an ICC value in the
published article, we will either obtain this value from similar
studies or we will estimate the ICC value. We will not present
results from cluster-randomized trials that are not adjusted for
clustering. If we estimate the ICC value, wewill perform sensitivity
analyses to investigate the robustness of our analyses.
If we identify studies for inclusion that have multiple intervention
arms, we will include data from these studies by either combining
treatment arms, or by splitting the control group so that we only
include participants once in the meta-analysis.
Dealing with missing data
We will attempt to contact the study authors to obtain missing
data when the lack of reporting of necessary data restricts the use
of the study. We anticipate that we may not be able to reach the
study author(s) of older publications. We will use an available-case
analysis, unless incomplete outcome data is such that we consider
the study to be at high risk of bias; in which case we may use
imputation to investigate the impact of this missing data.
Assessment of heterogeneity
We will examine the included studies to determine whether there
is heterogeneity in terms of co-intervention, level of supportive
care available, and risk of bias in the included studies.
We will inspect forest plots visually to assess whether statistical
heterogeneity is present. We will deem CIs that do not overlap as
an indication of statistical heterogeneity. We will also perform the
Chi² test using a cut-off point of P < 0.10 to indicate statistical het-
erogeneity, and we will use the I² statistic to quantify heterogene-
ity. We will interpret the I² statistic value according to guidance
from the Cochrane Handbook of Systematic Reviews of Interventions
(Higgins 2011a).
Assessment of reporting biases
If applicable, we will use funnel plot analysis or statistical tests
(such as the Egger regression test), or both, to assess for publication
bias. We will only perform funnel plot analysis if there are more
than 10 studies in any meta-analysis.
Data synthesis
We will consider performing a meta-analysis using Review Man-
ager 5 (RevMan 5) if it is appropriate to do so (RevMan 2014). If
it is inappropriate to perform a meta analysis, we will present the
results in tables.
For observational studies, whenever possible, we will combine the
adjusted point estimates and standard errors in the logarithm scale
using the generic inverse-variance random-effects methods. We
will perform meta-analysis if appropriate; although in observa-
tional studies with a high risk of bias, this will be to illustrate the
potential size of the effect of confounding.
We will use the GRADE approach to assess the certainty of the
evidence and we will create ’Summary of findings’ tables and Evi-
dence Profiles (GRADEpro 2015). Data from observational stud-
ies will start as low quality, but we may upgrade this to moderate
or high quality if the pooled estimates reveal a large magnitude of
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effect, negligible concerns about confounders, or a strong dose-
response gradient.
If there are differences within populations we combine in meta-
analyses that impact upon treatment effect, such as dosing, sup-
portive care, or age, we will use the random-effects model to reflect
this.
Subgroup analysis and investigation of heterogeneity
If unexplained heterogeneity occurs we will perform subgroup
analyses of the results to assess whether the effect of ribavirin is
influenced by any of the following factors.
• Severity of symptoms: severe, moderate, mild.
• Early and late treatment: number of days from onset of
symptoms.
• Duration of treatment, presence of severe gastrointestinal
symptoms and route of administration.
• Age (children versus adults). Children are defined as under
16 years of age.
Sensitivity analysis
If we estimate an ICC to adjust the results from cluster trials, we
will perform sensitivity analyses to investigate the robustness of
our analyses. If necessary we will perform a sensitivity analysis and
consider exclude studies that are at high risk of bias according to
the Cochrane Risk of Bias tool for RCTs (Higgins 2011b), and
serious risk of bias according to ROBINS-I tool for observational
studies (Sterne 2016).
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A P P E N D I C E S
Appendix 1. MEDLINE (PubMed) search strategy
1) “Hemorrhagic Fever, Crimean”[Mesh]) OR “Hemorrhagic Fever Virus, Crimean-Congo”[Mesh])
2) CCHF OR “Crimean Congo hemorrhagic fever” or “Crimean Congo haemorrhagic fever” Field: Title/Abstract
3) 1 or 2
4) “ribavirin”[MeSH Terms] OR “ribavirin”[All Fields]
5) 3 and 4
This is the preliminary search strategy for MEDLINE (Pubmed) and will be adapted for other electronic databases. We will report all
search strategies in full in the final version of the review.
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